You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 1147-H Novel immunotherapy regiment approach for pancreatic ductal adenocarcinoma (PDCA) using human MUC1 transgenic mice (MUC1.tg) model: optimizing conditions for MVA vaccine evaluation

Citation Tools

Article menu

Download PDFPDF

Regular Abstracts – Part 2
Immune-Stimulants and Immune Modulators
1147-H Novel immunotherapy regiment approach for pancreatic ductal adenocarcinoma (PDCA) using human MUC1 transgenic mice (MUC1.tg) model: optimizing conditions for MVA vaccine evaluation

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Silva L, Oruganti S, Cardona MR, et al
1147-H Novel immunotherapy regiment approach for pancreatic ductal adenocarcinoma (PDCA) using human MUC1 transgenic mice (MUC1.tg) model: optimizing conditions for MVA vaccine evaluation
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1147-H